What is Adanate?
Adanate is dedicated to advancing patient care by developing innovative products within the critical fields of oncology and immunology. Based in California, the company's core mission involves the rigorous translation of scientific concepts into market-ready solutions. This strategic focus positions Adanate to address significant unmet needs in disease treatment and patient management, leveraging cutting-edge research and development to create impactful therapies.
How much funding has Adanate raised?
Adanate has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2021): $30M with participation from Westlake Village BioPartners and Avalon Ventures
Key Investors in Adanate
Westlake Village BioPartners
Westlake BioPartners is a life science venture capital firm focused on investing in world-class entrepreneurs to create innovative biotech companies. Based in the Los Angeles biotech community, the firm incubates promising companies that aim to transform scientific breakthroughs into effective treatments for patients.
Avalon Ventures
Avalon Ventures is a venture capital firm with over 30 years of experience focusing on seed and early-stage companies, particularly in the life sciences and information technology sectors. The firm is driven by a team of former entrepreneurs who are passionate about supporting disruptive ideas in dynamic market environments.
What's next for Adanate?
The recent major strategic investment signals a pivotal growth phase for Adanate, likely enabling the company to accelerate its product development pipelines and expand its market reach. This capital infusion is expected to support further research, clinical trials, and the scaling of operations necessary to bring its promising oncology and immunology treatments to patients. Adanate's trajectory suggests a strong commitment to innovation and a clear path toward becoming a key player in its therapeutic areas.
See full Adanate company page
